ArticleFrontiers in oncology2022

Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.

Ran You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.